article thumbnail

STAT+: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

STAT

Preliminary results from the study — just the second to show that CRISPR-based gene editing can be delivered systemically and performed in vivo, or inside the body — found that the treatment, NTLA-2002, reduced levels of the disease-causing protein, kallikrein, by 65% and 92% in the low- and high-dose cohort, respectively.

142
142
article thumbnail

Leprosy potentially endemic in Central Florida

Pharmaceutical Technology

The proportion of cases found in migrants to Florida has decreased significantly since 2002 while cases in US residents has risen.

98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug

STAT

Here’s the backstory: Enbrel was the centerpiece of a 2002 deal in which Amgen acquired another company called Immunex that had developed the medicine. But Public Citizen maintains Medicare officials should consider the ongoing cost of the patenting tactics when negotiating a price.

133
133
article thumbnail

Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular Carcinoma

PharmaShots

Shots: The companies collaborated to evaluate the safety, tolerability, PK, PD & preliminary antitumor activity of OTX-2002 as monotx. The preliminary results from the monotx.

article thumbnail

Incyte plots Delaware expansion as it looks to re-wed commercial, medical teams in its home state

Fierce Pharma

. | Incyte revealed plans to purchase buildings at 1100 North King Street and 1100 North French street in downtown Wilmington, Delaware, where the company got its start back in 2002.

77
article thumbnail

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT

Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

98
article thumbnail

Watch: Blockbuster drug Humira has new competition. Here’s why that matters

STAT

Humira has been the world’s best-selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

95